VIVUS (VVUSQ) Stock Price, News & Analysis

Company Overview

VIVUS, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapies addressing obesity, sexual health and sleep-disordered breathing. The company’s research and development efforts focus on creating innovative treatments that meet unmet medical needs and improve patient quality of life.

VIVUS’s lead product, Qsymia, is an FDA-approved oral therapy for chronic weight management in adults with obesity or overweight conditions accompanied by weight-related comorbidities. In addition to its obesity portfolio, VIVUS has developed and out-licensed Stendra (avanafil), a treatment for erectile dysfunction, and continues to explore next-generation compounds in respiratory and metabolic disease areas.

Founded in 1991 and headquartered in Foster City, California, VIVUS primarily serves the U.S. market under FDA regulatory oversight. The company maintains a focused pipeline of investigational therapies and leverages strategic collaborations to advance clinical programs. VIVUS’s management team brings experience in drug development and commercialization within the biotechnology sector, guiding its mission to deliver new treatment options for patients.

Key Stats

• Today's Range: $0.12 to $0.12
• 50-Day Range: $0.12 to $0.12
• 52-Week Range: $0.07 to $4.55
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 6/15/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:VVUSQ
• CIK: N/A
• Web: www.vivus.com
• Phone: 650-934-5200
• Fax: 650-934-5389
• Employees: 57
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A